These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
842 related articles for article (PubMed ID: 34048680)
1. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Straus DJ; Długosz-Danecka M; Connors JM; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Munoz J; Lee HJ; Kim WS; Advani R; Ansell SM; Younes A; Gallamini A; Liu R; Little M; Fenton K; Fanale M; Radford J Lancet Haematol; 2021 Jun; 8(6):e410-e421. PubMed ID: 34048680 [TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Straus DJ; Długosz-Danecka M; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Connors JM; Radford J; Munoz J; Kim WS; Advani R; Ansell SM; Younes A; Miao H; Liu R; Fenton K; Forero-Torres A; Gallamini A Blood; 2020 Mar; 135(10):735-742. PubMed ID: 31945149 [TBL] [Abstract][Full Text] [Related]
3. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. Ansell SM; Radford J; Connors JM; Długosz-Danecka M; Kim WS; Gallamini A; Ramchandren R; Friedberg JW; Advani R; Hutchings M; Evens AM; Smolewski P; Savage KJ; Bartlett NL; Eom HS; Abramson JS; Dong C; Campana F; Fenton K; Puhlmann M; Straus DJ; N Engl J Med; 2022 Jul; 387(4):310-320. PubMed ID: 35830649 [TBL] [Abstract][Full Text] [Related]
4. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. Connors JM; Jurczak W; Straus DJ; Ansell SM; Kim WS; Gallamini A; Younes A; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Oki Y; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Chen R; Ramchandren R; Zinzani PL; Cunningham D; Rosta A; Josephson NC; Song E; Sachs J; Liu R; Jolin HA; Huebner D; Radford J; N Engl J Med; 2018 Jan; 378(4):331-344. PubMed ID: 29224502 [TBL] [Abstract][Full Text] [Related]
5. Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Ramchandren R; Advani RH; Ansell SM; Bartlett NL; Chen R; Connors JM; Feldman T; Forero-Torres A; Friedberg JW; Gopal AK; Gordon LI; Kuruvilla J; Savage KJ; Younes A; Engley G; Manley TJ; Fenton K; Straus DJ Clin Cancer Res; 2019 Mar; 25(6):1718-1726. PubMed ID: 30617130 [TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220 [TBL] [Abstract][Full Text] [Related]
7. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483 [TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hutchings M; Radford J; Ansell SM; Illés Á; Sureda A; Connors JM; Sýkorová A; Shibayama H; Abramson JS; Chua NS; Friedberg JW; Kořen J; LaCasce AS; Molina L; Engley G; Fenton K; Jolin H; Liu R; Gautam A; Gallamini A Hematol Oncol; 2021 Apr; 39(2):185-195. PubMed ID: 33462822 [TBL] [Abstract][Full Text] [Related]
9. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Evens AM; Connors JM; Younes A; Ansell SM; Kim WS; Radford J; Feldman T; Tuscano J; Savage KJ; Oki Y; Grigg A; Pocock C; Dlugosz-Danecka M; Fenton K; Forero-Torres A; Liu R; Jolin H; Gautam A; Gallamini A Haematologica; 2022 May; 107(5):1086-1094. PubMed ID: 34162178 [TBL] [Abstract][Full Text] [Related]
13. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial. Fornecker LM; Lazarovici J; Aurer I; Casasnovas RO; Gac AC; Bonnet C; Bouabdallah K; Feugier P; Specht L; Molina L; Touati M; Borel C; Stamatoullas A; Nicolas-Virelizier E; Pascal L; Lugtenburg P; Di Renzo N; Vander Borght T; Traverse-Glehen A; Dartigues P; Hutchings M; Versari A; Meignan M; Federico M; André M; J Clin Oncol; 2023 Jan; 41(2):327-335. PubMed ID: 35867960 [TBL] [Abstract][Full Text] [Related]
14. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Kreissl S; Goergen H; Buehnen I; Kobe C; Moccia A; Greil R; Eichenauer DA; Zijlstra JM; Markova J; Meissner J; Feuring-Buske M; Soekler M; Beck HJ; Willenbacher W; Ludwig WD; Pabst T; Topp MS; Hitz F; Bentz M; Keller UB; Kühnhardt D; Ostermann H; Hertenstein B; Aulitzky W; Maschmeyer G; Vieler T; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Dietlein M; Engert A; Borchmann P; Lancet Haematol; 2021 Jun; 8(6):e398-e409. PubMed ID: 34048679 [TBL] [Abstract][Full Text] [Related]
15. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ; Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma. Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study. Vijenthira A; Chan K; Cheung MC; Prica A Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928 [TBL] [Abstract][Full Text] [Related]
18. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014 [TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL; Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562 [TBL] [Abstract][Full Text] [Related]